Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies
Anita H Clayton,1 Suresh Durgam,2 Xiongwen Tang,2 Changzheng Chen,2 Adam Ruth,3 Carl Gommoll2 1Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, 2Forest Research Institute, Jersey City, NJ, 3Prescott Medical Communications Group, Chicago, IL, USA B...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-06-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Subjects: | |
| Online Access: | https://www.dovepress.com/characterizing-sexual-function-in-patients-with-generalized-anxiety-di-peer-reviewed-fulltext-article-NDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849424713053372416 |
|---|---|
| author | Clayton A Durgam S Tang X Chen C Ruth A Gommoll C |
| author_facet | Clayton A Durgam S Tang X Chen C Ruth A Gommoll C |
| author_sort | Clayton A |
| collection | DOAJ |
| description | Anita H Clayton,1 Suresh Durgam,2 Xiongwen Tang,2 Changzheng Chen,2 Adam Ruth,3 Carl Gommoll2 1Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, 2Forest Research Institute, Jersey City, NJ, 3Prescott Medical Communications Group, Chicago, IL, USA Background: Vilazodone has been shown to reduce core symptoms of generalized anxiety disorder (GAD) in three randomized, double-blind, placebo-controlled trials. Since sexual dysfunction (SD) is not well characterized in GAD, a post hoc analysis of these trials was conducted to evaluate the effects of vilazodone on sexual functioning in GAD patients. Materials and methods: Data were pooled from one fixed-dose trial of vilazodone 20 and 40 mg/day (NCT01629966) and two flexible-dose studies of vilazodone 20–40 mg/day (NCT01766401, NCT01844115) in adults with GAD. Sexual functioning was assessed using the Changes in Sexual Functioning Questionnaire (CSFQ). Outcomes included mean change from baseline to end of treatment (EOT) in CSFQ total score and percentage of patients shifting from SD at baseline (CSFQ total score ≤47 for males, ≤41 for females) to normal functioning at EOT. Treatment-emergent adverse events related to sexual functioning were also analyzed. Results: A total of 1,373 patients were included in the analyses. SD at baseline was more common in females (placebo, 46.4%; vilazodone, 49%) than in males (placebo, 35.1%; vilazodone, 40.9%). CSFQ total score improvement was found in both females (placebo, +1.2; vilazodone, +1.6) and males (placebo, +2.1; vilazodone, +1.0), with no statistically significant differences between treatment groups. The percentage of patients who shifted from SD at baseline to normal sexual functioning at EOT was higher in males (placebo, 40.6%; vilazodone, 35.7%) than in females (placebo, 24.9%; vilazodone, 34.9%); no statistical testing was performed. Except for erectile dysfunction and delayed ejaculation in vilazodone-treated males (2.4% and 2.1%, respectively), no treatment-emergent adverse events related to sexual functioning occurred in ≥2% of patients in either treatment group. Conclusion: Approximately 35%–50% of patients in the vilazodone GAD studies had SD at baseline. Vilazodone and placebo had similar effects on CSFQ outcomes in both females and males, indicating a limited adverse impact on sexual functioning with vilazodone. Keywords: vilazodone, generalized anxiety disorder, sexual dysfunction, clinical trials, post hoc analysis |
| format | Article |
| id | doaj-art-c967c2494ff04b1db0ee5d359f659a8e |
| institution | Kabale University |
| issn | 1178-2021 |
| language | English |
| publishDate | 2016-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj-art-c967c2494ff04b1db0ee5d359f659a8e2025-08-20T03:30:03ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212016-06-01Volume 12Issue 11467147627538Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studiesClayton A0Durgam STang XChen CRuth AGommoll CDepartment of Psychiatry and Neurobehavioral SciencesAnita H Clayton,1 Suresh Durgam,2 Xiongwen Tang,2 Changzheng Chen,2 Adam Ruth,3 Carl Gommoll2 1Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, 2Forest Research Institute, Jersey City, NJ, 3Prescott Medical Communications Group, Chicago, IL, USA Background: Vilazodone has been shown to reduce core symptoms of generalized anxiety disorder (GAD) in three randomized, double-blind, placebo-controlled trials. Since sexual dysfunction (SD) is not well characterized in GAD, a post hoc analysis of these trials was conducted to evaluate the effects of vilazodone on sexual functioning in GAD patients. Materials and methods: Data were pooled from one fixed-dose trial of vilazodone 20 and 40 mg/day (NCT01629966) and two flexible-dose studies of vilazodone 20–40 mg/day (NCT01766401, NCT01844115) in adults with GAD. Sexual functioning was assessed using the Changes in Sexual Functioning Questionnaire (CSFQ). Outcomes included mean change from baseline to end of treatment (EOT) in CSFQ total score and percentage of patients shifting from SD at baseline (CSFQ total score ≤47 for males, ≤41 for females) to normal functioning at EOT. Treatment-emergent adverse events related to sexual functioning were also analyzed. Results: A total of 1,373 patients were included in the analyses. SD at baseline was more common in females (placebo, 46.4%; vilazodone, 49%) than in males (placebo, 35.1%; vilazodone, 40.9%). CSFQ total score improvement was found in both females (placebo, +1.2; vilazodone, +1.6) and males (placebo, +2.1; vilazodone, +1.0), with no statistically significant differences between treatment groups. The percentage of patients who shifted from SD at baseline to normal sexual functioning at EOT was higher in males (placebo, 40.6%; vilazodone, 35.7%) than in females (placebo, 24.9%; vilazodone, 34.9%); no statistical testing was performed. Except for erectile dysfunction and delayed ejaculation in vilazodone-treated males (2.4% and 2.1%, respectively), no treatment-emergent adverse events related to sexual functioning occurred in ≥2% of patients in either treatment group. Conclusion: Approximately 35%–50% of patients in the vilazodone GAD studies had SD at baseline. Vilazodone and placebo had similar effects on CSFQ outcomes in both females and males, indicating a limited adverse impact on sexual functioning with vilazodone. Keywords: vilazodone, generalized anxiety disorder, sexual dysfunction, clinical trials, post hoc analysishttps://www.dovepress.com/characterizing-sexual-function-in-patients-with-generalized-anxiety-di-peer-reviewed-fulltext-article-NDTvilazodonegeneralized anxiety disordersexual dysfunctionclinical trialspost hoc analysis |
| spellingShingle | Clayton A Durgam S Tang X Chen C Ruth A Gommoll C Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies Neuropsychiatric Disease and Treatment vilazodone generalized anxiety disorder sexual dysfunction clinical trials post hoc analysis |
| title | Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies |
| title_full | Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies |
| title_fullStr | Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies |
| title_full_unstemmed | Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies |
| title_short | Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies |
| title_sort | characterizing sexual function in patients with generalized anxiety disorder a pooled analysis of amp nbsp three vilazodone studies |
| topic | vilazodone generalized anxiety disorder sexual dysfunction clinical trials post hoc analysis |
| url | https://www.dovepress.com/characterizing-sexual-function-in-patients-with-generalized-anxiety-di-peer-reviewed-fulltext-article-NDT |
| work_keys_str_mv | AT claytona characterizingsexualfunctioninpatientswithgeneralizedanxietydisorderapooledanalysisofampnbspthreevilazodonestudies AT durgams characterizingsexualfunctioninpatientswithgeneralizedanxietydisorderapooledanalysisofampnbspthreevilazodonestudies AT tangx characterizingsexualfunctioninpatientswithgeneralizedanxietydisorderapooledanalysisofampnbspthreevilazodonestudies AT chenc characterizingsexualfunctioninpatientswithgeneralizedanxietydisorderapooledanalysisofampnbspthreevilazodonestudies AT rutha characterizingsexualfunctioninpatientswithgeneralizedanxietydisorderapooledanalysisofampnbspthreevilazodonestudies AT gommollc characterizingsexualfunctioninpatientswithgeneralizedanxietydisorderapooledanalysisofampnbspthreevilazodonestudies |